Selected Publications

Kashyap AS, Fernandez-Rodriguez L, Zhao Y, Monaco G, Trefny MP, Yoshida N, Martin K, Sharma A, Olieric N, Shah P, Stanczak M, Kirchhammer N, Park SM, Wieckowski S, Laubli H, Zagani R, Kasenda B, Steinmetz MO, Reinecker HC, Zippelius A.(2019) GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses. Cell Rep., 28(13):3367-3380.e8.

D'Amico L, Menzel U, Prummer M, Müller P, Buchi M, Kashyap A, Haessler U, Yermanos A, Gébleux R, Briendl M, Hell T, Wolter FI, Beerli RR, Truxova I, Radek Š, Vlajnic T, Grawunder U, Reddy S, Zippelius A. (2019) A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J Immunother Cancer, (2019)7:16

Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S, Tzankov A, Tietze L, Lardinois D, Heinzelmann-Schwarz V, von Bergwelt-Baildon MS, Zhang W, Lenz HJ, Han Y, Amos CI, Syedbasha M, Egli A, Stenner F, Speiser DE, Varki A, Zippelius A, Läubli H. (2018) Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Invest, 128(11):4912-4923

Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny MP, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, Savic Prince S, Wiese M, Lardinois D, Ho PC, Klein C, Karanikas V, Mertz KD, Schumacher TN and Zippelius A. (2018), Transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nature Medicine, 24(7):994-1004

Läubli H, Müller P, D’Amico L, Buchi M, Kashyap AS, Zippelius A. (2018) The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models. Cancer Immunology, 67(5):815-824

Läubli H, Koelzer VH, Matter MS, Herzig P, Dolder Schlienger B, Wiese M, Lardinois D, Mertz KD & Zippelius A. (2017) The Tcell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. Onco Immunology, 7(2):e1386362

Müller P, Rothschild SI, Arnold W, Hirschmann P, Horvath L, Bubendorf L, Savic S, Zippelius A. (2016) Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. Cancer Immunol Immunother. 65(1):1-11

Müller P, Kreuzaler M, Khan T, Thommen DS, Martin K,Glatz K, Savic S, Harbeck N, Nitz U, Gluz O, et al. (2015)Trastuzumab emtansine (T-DM1) renders HER2+ breastcancer highly susceptible to CTLA-4/PD-1 blockade.Sci. Transl. Med. 7, 315ra188

Schreiner J, Thommen DS, Herzig P, Bacac M, Klein C, RollerA, Belousov A, Levitsky A, Savic S, Moersig W, et al.(2015) Expression of inhibitory receptors on intratumoralT cells modulates the activity of a T cell-bispecific antibodytargeting folate receptor. Oncoimmunology 5(2),e1062969

Thommen DS, Schreiner J, Müller P, Herzig P, Roller A,Belousov A, Umana P, Pisa P, Klein C, Bacac M, et al.(2015) Progression of lung cancer is associated with increaseddysfunction of T cells defined by coexpressionof multiple inhibitory receptors. Cancer Immunol Res3(12), 1344–55

Zippelius A, Schreiner J, Herzig P, Müller P. (2015) InducedPD-L1 expression mediates acquired resistance to agonisticanti-CD40 treatment. Cancer Immunol Res 3(3),236–244

Müller P, Martin K, Theurich S, Schreiner J, Savic S, TerszowskiG, Lardinois D, Heinzelmann-Schwarz VA,Schlaak M, Kvasnicka, et al. (2014) Microtubule-depolymerizingagents used in antibody-drug conjugatesinduce antitumor immunity by stimulation of dendriticcells. Cancer Immunol Res 2(8), 741–755